Novartis’ Zolgensma shows ‘continued benefit’ in SMA patients by Selina McKee | Oct 1, 2020 | News | 0 66.7% of patients in the intent-to-treat population were able to feed orally without the need for feeding support Read More
EU approves Novartis’ SMA gene therapy Zolgensma by Selina McKee | May 20, 2020 | News | 0 Discussions with EU governments and reimbursement agencies are ongoing to agree on terms of an innovative ‘Day One’ access programme Read More
Novartis’ SMA therapy gets US priority review by Selina McKee | Dec 4, 2018 | News | 0 US regulators have accepted for review Novartis’ Biologics License Application for Zolgensma, an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1. Read More